Double-/Triple-Hit high-grade B-cell Lymphoma
Conditions
Interventions
experimental group:Venetoclax combined with DA-EPOCH-R
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed DH/TH HGBL by pathology; 2. Aged from 18 to 75 years; 3. ECOG 0-3; 4. Obtain the informed consent signed by the patient or his family.
Exclusion criteria
Exclusion criteria: 1. Received systemic or local treatment including chemotherapy in the first three weeks; 2. Blood bilirubin >2mg/dl(35µmol/L), AST/ALT was more than 2 times of the upper limit of normal, serum creatinine was more than 177µmol/L, the creatinine clearance rate was less than 60ml/min; 3. Normal heart function: EF <=50%; 4. The expected survival time was less than 3 months; 5. Chronic or current active infectious diseases requiring systemic antibiotics, antifungal agents or antiviral therapy; 6. Other concurrent and uncontrollable factors are considered by the researchers to affect the medical status of patients participating in the study, psychiatric patients or other patients who are known or suspected to be unable to fully comply with the study protocol; 7. People living with HIV; 8. Pregnant or lactating women,women/men with planned parenthood during the study period or within 3 months after treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Objective response rate;Progression free survival;Safety; | — |
Countries
China
Contacts
Public ContactJin Jie/Yu Wenjuan
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed